drugset / Trial / NCT00671190

Safety and Efficacy of Ramelteon in Healthy Subjects

NCT00671190

Phase 2 Completed 75 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the phase-advance in circadian rhythms in healthy adults subjects taking ramelteon, once daily (QD).

Timeline

Start
2005-03
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 1 mg Oral
Subject Ramelteon Unknown 2 mg Oral
Subject Ramelteon Unknown 4 mg Oral
Subject Ramelteon Unknown 8 mg Oral

Indications